iHealth Labs Reports Repurchase of 6.219 Million Shares for RMB 231 Million; 2023 Global MedTech Top 100 List Released

Andon Health Repurchases 6.219 Million Shares for 231 Million Yuan

On September 1, 2023, Andon Health announced that, as of today, the company has cumulatively repurchased 6.219 million shares through its dedicated securities account for stock repurchases via centralized bidding. These shares account for 1.28% of the company's total share capital. The highest transaction price was 37.99 yuan per share, and the lowest was 35.70 yuan per share. The total amount paid was 231 million yuan (excluding transaction fees). (Source: Zhitong Finance)

Top 100 Global Medical Device Companies in 2023 Released

On August 31, 2023, it was reported that Medical Design and Outsourcing, a well-known industry media outlet, released the 2023 list of the top 100 global medical device companies (Medtech Big 100), with Mindray Medical and MicroPort Medical both making the cut. Among them, the companies entering the top ten remained consistent with last year, with only minor fluctuations in rankings, but the "top three" positions remained unchanged. The rankings are as follows: Medtronic, Johnson & Johnson Medical, Siemens Healthineers, Merun, Philips, Stryker, GE Healthcare, Cardinal Health, Baxter, and Abbott. As representatives of Chinese companies, both Mindray and MicroPort were included in the top 100 for the second time. MicroPort ranked 77th, consistent with last year; Mindray ranked 27th, achieving a breakthrough by moving up five places from the previous ranking. (Source: Arterial Network)

Junshi Biosciences Director and Core Technical Staff, Feng Hui, Resigns

On September 1, 2023, Junshi Biosciences announced that Feng Hui, executive director and core technical personnel of the company, had applied to resign from his positions as Chief Operating Officer and other roles in subsidiaries due to personal reasons, effective August 31, 2023. After his resignation, Feng Hui will be transferred to serve as a non-executive director of the company. The company will hire him as a technical consultant to ensure the smooth progress and transition of relevant R&D work. After Feng Hui's departure, the responsibilities he handled will be taken over by Zhang Zhuobing, executive director and deputy general manager, and SHENGYAO (Yao Sheng), executive director and deputy general manager. Feng Hui's departure will not have a substantial impact on the company’s technology research and development or production operations, nor will it affect the integrity of the company’s core technologies and patent ownership.(Source: Zhitong Finance)

GE Healthcare's Cardiovascular Ultrasound Series Achieves Full Local Production in Wuxi

On August 31, 2023, it was reported that with the production of the VividTM Arctic Light flagship cardiovascular ultrasound diagnostic system at GE Healthcare's Wuxi base in China and its approval by the NMPA, the entire range of cardiovascular ultrasound products, including the VividTM T series, VividTM iq series, and VividTM Aurora series, has achieved full localization in China. This marks another significant milestone in GE Healthcare China’s “Full Localization” strategy and heralds a new chapter in the clinical application of locally produced cardiovascular ultrasound systems in China. The fully localized Vivid series not only incorporates GE Healthcare's most advanced imaging platform technology and ultrasound probe craftsmanship but also integrates artificial intelligence to comprehensively enhance image resolution, improve the quality of 4D ultrasound, and offer fully intelligent cardiac function quantification tools. It provides comprehensive clinical solutions across both structural and functional areas, playing a crucial role in interventional procedures for various structural heart diseases, radiofrequency ablation in electrophysiology (for atrial fibrillation treatment), and the diagnosis of subclinical cardiac dysfunction. (Source: Arterial Network)

Synthetic Biology Company Create Biotech Completes RMB 250 Million Series B Financing

Recently, Shanghai Cota Biotech Co., Ltd. (hereinafter referred to as "Cota Biotech") completed a B-round financing of 250 million RMB, jointly led by Hengxu Capital and Eight Roads Capital, with participation from Henan Huirong and Bits x Bites. Yuanqi Capital served as the exclusive financial advisor. This round of financing marks the fourth round completed by Cota Biotech in nearly two years since its establishment, accumulating nearly 500 million RMB in funding reserves. (Source: Arterial Network)

PILOT Gene Technologies Completes Nearly 100 Million Yuan in Series B Financing

Recently, PILOT Gene Technologies (Hangzhou) Co., Ltd. ("PILOT Gene"), a leading enterprise in China's digital PCR industry, announced the completion of a new round of financing worth nearly 100 million yuan. This round of financing was led by Simiao Capital, with existing shareholders also increasing their investment. Xuejian Capital served as the exclusive financial advisor for this round and will continue to act as the financial advisor. The funds will mainly be used for the research and development of fully automatic instruments and POCT equipment, subsequent production and sales of Class III reagent certificates, and the expansion of overseas business. (Source: Arterial Network)

ACCURDX Successfully Completes A+ Round Financing Worth Tens of Millions of Yuan

Recently, Shandong Aikeda Biotechnology Co., Ltd. ("ACCURDX") successfully completed a multi-million yuan A+ round of financing. This round was led by "Shandong New Momentum Fund," marking a new phase of rapid financing following the A round completed with co-investment from Yida Capital and CITIC Medical Fund. This investment reflects the capital market's strong interest in China’s coagulation sector, leveraging the opportunities presented by an improving macroeconomic environment and reinforcing support for the real economy. The proceeds will primarily be used for capacity expansion, R&D innovation, and new product development. (Source: Arterial Network)

Junshi Biosciences Completes Nearly 100 Million Yuan B+ Round Financing

Recently, Kangpu Biomedical Technology(Shanghai) Co., Ltd. (hereinafter referred to as "Kangpu Biomedical") announced the completion of a nearly RMB 100 million Series B+ financing round. This round was led by Yicun Capital, with continued support from existing shareholders including Northern Light Venture Capital, Longpan Investment, Yi Jing Capital, Ruihe Capital, and Ginkgo Valley Capital. WinX Capital served as the exclusive financial advisor. The proceeds from this financing will mainly be used to accelerate the clinical advancement of two molecular glue-ubiquitination degradation products with leading international progress, as well as preclinical research for multiple pipelines. (Source: Arterial Network)

Venus Medtech Releases 2023 H1 Performance Report

On August 31, 2023, Venus Medtech announced its 2023 interim results. In the first half of 2023, Venus Medtech achieved sales revenue of 256 million RMB, representing a year-on-year increase of 21.74%, meeting the expected growth target. Based on the "local profitization" strategy, the company realized commercial positive returns in the Chinese market by optimizing sales costs and expenses and improving operational efficiency. To date, the total implant volume of the company's main product, the VenusA series, in the Chinese market has exceeded 15,000 cases. In the first half of the year, Venus Medtech's overseas sales amounted to 22.49 million RMB, marking a year-on-year increase of 60.37%, mainly driven by the robust growth of VenusP-Valve, the first domestically produced transcatheter pulmonary valve replacement system to be launched in Europe. (Source: Zhitong Finance)

Hansoh Pharma Releases H1 2023 Earnings Report

On August 31, 2023, Hansoh Pharma announced its interim results for the six months ended June 30, 2023. The group reported revenue of RMB 4.511 billion (same unit hereinafter), representing a year-on-year increase of 1.73%; R&D expenditure reached RMB 929 million, marking a year-on-year increase of 25.77%; net profit attributable to owners of the parent company amounted to RMB 1.289 billion, reflecting a year-on-year decrease of 0.7%; basic earnings per share were RMB 0.22, and an interim dividend of HKD 7.07 cents per share is proposed. (Source: Zhitong Finance)

"The Administrative Measures for the Outpatient Treatment Benefits of Chronic and Special Diseases under the Basic Medical Insurance for Residents of Hunan Province" Will Be Officially Implemented

On September 1, 2023, the "Management Measures for Outpatient Treatment Benefits of Chronic and Special Diseases under the Basic Medical Insurance for Residents of Hunan Province," issued by the Hunan Provincial Medical Insurance Bureau, will officially come into effect, with a validity period of five years. Forty-seven diseases, including malignant tumors, coronary heart disease, rheumatoid arthritis, and pneumoconiosis, have been included in the reimbursement scope for outpatient chronic and special diseases. The document stipulates that for policy-covered expenses incurred by insured individuals who meet the conditions for outpatient treatment benefits for chronic and special diseases, there will be no deductible. Within the prescribed drug cost limit under the outpatient treatment policy for chronic and special diseases, costs will be reimbursed at a rate of 70%. The Measures clarify that insured individuals will begin to enjoy outpatient treatment benefits for chronic and special diseases from the following month after approval. Payment limits are generally managed on a monthly basis, and any unused portion within the quarter will be reset to zero. According to relevant policies allowing for long-term prescriptions, payment limits can be managed on a quarterly basis. During hospitalization, insured individuals will temporarily suspend their eligibility for outpatient treatment benefits for chronic and special diseases. (Source: Arterial Network)